EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The lipocalin saga: Insights into its role in cancer-associated cachexia

Srusti Dave, Bhoomika Patel

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · 2025-03 · 1871 (3) · 167684

DOI: 10.1016/j.bbadis.2025.167684 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2025-03. Verfasst von Srusti Dave und 1 weiteren Autor:innen. Beteiligte Einrichtung: National Forensic Sciences University, Gandhinagar 382007, Gujarat, India. Hauptthemen laut MEDLINE: Cachexia, Neoplasms, Lipocalin-2. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 112 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer-associated cachexia (CAC) is a debilitating condition, observed in patients with advanced stages of cancer. It is marked by ongoing weight loss, weakness, and nutritional impairment. Lower tolerance of chemotherapeutic agents and radiation therapy makes it difficult to treat CAC. Anorexia is a significant contributor to worsening CAC. Anorexia can be found in the early or advanced stages of cancer. Anorexia in cancer patients arises from a confluence of factors. Tumor-related inflammatory cytokines can directly impact the gastrointestinal tract, leading to dysphagia and compromised gut function. Additionally, increased serotonin and hormonal disruptions lead to early satiety, suppressing appetite. Due to the complexities in the pathogenesis of the disease, identifying druggable targets is a challenge. Research is ongoing to identify novel targets for the treatment of this condition. Recent research suggests a potential link between elevated levels of Lipocalin 2 (LCN2) and cachexia in cancer patients. LCN2, a glycoprotein primarily released by neutrophils, is implicated in numerous illnesses, including skin disorders, cancer, atherosclerosis, and type 2 diabetes. LCN2 suppresses hunger by binding to the melanocortin-4 receptors. Several in vitro, in vivo, and clinical studies indicate the association between LCN2 levels and appetite suppression. Further research should be explored emphasizing the significance of well-crafted clinical trials to confirm LCN2's usefulness as a therapeutic target and its ability to help cancer patients who are suffering from the fatal hallmark of cachexia. This review explores LCN2's function in the multifaceted dynamics of CAC and anorexia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CachexiaNeoplasmsLipocalin-2HumansAnimalsAnorexia

Stichwörter der Autor:innen

AnorexiaCancer-associated cachexiaLipocalin 2Skeletal muscle wasting

Substanzen

Lipocalin-2LCN2 protein, human

Autor:innen und Institutionen

  • National Forensic Sciences University, Gandhinagar 382007, Gujarat, India.
  • National Forensic Sciences University, Gandhinagar 382007, Gujarat, India. Electronic address: bhoomika.patel@nfsu.ac.in.

Zitieren

APA

Dave, S., & Patel, B. (2025). The lipocalin saga: Insights into its role in cancer-associated cachexia. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1871(3), 167684. https://doi.org/10.1016/j.bbadis.2025.167684

Vancouver

Dave S, Patel B. The lipocalin saga: Insights into its role in cancer-associated cachexia. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2025;1871(3):167684. doi:10.1016/j.bbadis.2025.167684

BibTeX
@article{Dave2025,
  author = {Dave, Srusti and Patel, Bhoomika},
  title = {The lipocalin saga: Insights into its role in cancer-associated cachexia},
  journal = {Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease},
  year = {2025},
  volume = {1871},
  number = {3},
  pages = {167684},
  doi = {10.1016/j.bbadis.2025.167684}
}
Kostenlos starten →